Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1;72(4):449-454.
doi: 10.2337/db22-0709.

The Effect of Glucagon-Like Peptide 1 Receptor Blockade on Glucagon-Induced Stimulation of Insulin Secretion

Affiliations

The Effect of Glucagon-Like Peptide 1 Receptor Blockade on Glucagon-Induced Stimulation of Insulin Secretion

Rahele A Farahani et al. Diabetes. .

Abstract

Data from transgenic rodent models suggest that glucagon acts as an insulin secretagogue by signaling through the glucagon-like peptide 1 receptor (GLP-1R) present on β-cells. However, its net contribution to physiologic insulin secretion in humans is unknown. To address this question, we studied individuals without diabetes in two separate experiments. Each subject was studied on two occasions in random order. In the first experiment, during a hyperglycemic clamp, glucagon was infused at 0.4 ng/kg/min, increasing by 0.2 ng/kg/min every hour for 5 h. On one day, exendin-9,39 (300 pmol/kg/min) was infused to block GLP-1R, while on the other, saline was infused. The insulin secretion rate (ISR) was calculated by nonparametric deconvolution from plasma concentrations of C-peptide. Endogenous glucose production and glucose disappearance were measured using the tracer-dilution technique. Glucagon concentrations, by design, did not differ between study days. Integrated ISR was lower during exendin-9,39 infusion (213 ± 26 vs. 191 ± 22 nmol/5 h, saline vs. exendin-9,39, respectively; P = 0.02). In the separate experiment, exendin-9,39 infusion, compared with saline infusion, also decreased the β-cell secretory response to a 1-mg glucagon bolus. These data show that, in humans without diabetes, glucagon partially stimulates the β-cell through GLP-1R.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Glucose (A), glucagon (B), insulin (C), C-peptide (D), insulin secretion rate (E), and area under the curve (AUC) of insulin secretion rate (F) during saline (open circles) and exendin-9,39 infusion (solid circles) in response to a variable glucagon infusion. Values plotted are means ± SEMs.
Figure 2
Figure 2
Glucose infusion rate (A), specific activity (B), EGP (C), and glucose disappearance (D) during saline (open circles) and exendin-9,39 infusion (solid circles) in response to a variable glucagon infusion. Values plotted are means ± SEMs.
Figure 3
Figure 3
Glucose (A), insulin (B), and C-peptide (C) during saline (open circles) and exendin-9,39 infusion (solid circles) in response to a glucagon bolus. Values plotted are means ± SEMs.

References

    1. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 1999;277:E283–E290 - PubMed
    1. Robertson RP, Raymond RH, Lee DS, et al. .; Beta Cell Project Team of the Foundation for the NIH Biomarkers Consortium . Arginine is preferred to glucagon for stimulation testing of β-cell function. Am J Physiol Endocrinol Metab 2014;307:E720–E727 - PMC - PubMed
    1. Finan B, Capozzi ME, Campbell JE. Repositioning glucagon action in the physiology and pharmacology of diabetes. Diabetes 2020;69:532–541 - PMC - PubMed
    1. Sharma A, Varghese RT, Shah M, et al. . Impaired insulin action is associated with increased glucagon concentrations in nondiabetic humans. J Clin Endocrinol Metab 2018;103:314–319 - PMC - PubMed
    1. Moens K, Flamez D, Van Schravendijk C, Ling Z, Pipeleers D, Schuit F. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors. Diabetes 1998;47:66–72 - PubMed

Publication types

LinkOut - more resources